FORMULATION AND IN VITRO EVALUATION OF SALBUTAMOL SULPHATE AND THEOPHYLLINE EXTENDED-RELEASE TABLETS USING MODIFIED POLYMERS
Objective: The main objective of this research work was to design, prepare and evaluate extended release (ER) tablets of anti-asthmatic drugs (salbutamol sulphate and theophylline) by direct compression method using diverse ratios of hydroxypropyl methylcellulose (HPMC K100M) and ethyl cellulose (EC) along with some other excipients.
Methods: Extended-release matrix tablets of salbutamol sulphate and theophylline were successfully fabricated by direct compression method and coded the formulations as F1 to F7 depending on the ratios of modified polymers. The core tablets composed of hydrophilic polymers of various ratios that allow the discharge of drugs at a controlled rate after coming in contact with the aqueous medium. The designed tablets were subjected to various assessment parameters i.e. friability test, hardness test, drug content consistency and In vitro dissolution tests.
Results: Prepared formulations were subjected to various assessment parameters and the findings obtained were within the prescribed limit. To perform the in vitro drug dissolution tests of fabricated tablets, the calibration plots of pure drugs using various solvents i.e. 0.1N HCl, phosphate buffer (pH 6.8) and distilled water were plotted. Dosage forms F1-F7 containing ethyl cellulose and HPMC K100M in various concentration demonstrates the prolonged medications discharge for up to 8 h, among these formulations, F6 shows 95.32Â±0.24 % for salbutamol sulphate and 94.19Â±0.39 % for theophylline release at the end of 8 h. This finding reveals that a particular window of concentrations of ethylcellulose and HPMC K100M was capable of providing prolonged drugs discharge.
Conclusion: The results obtained in this research work clearly showed a promising potential of extended-release tablets containing a specific ratio of HPMC K100M and ethylcellulose as a release rate controlling polymers for effective treatment of asthma and chronic obstructive pulmonary diseases (COPD).
2. Arafat M. Approaches to achieve an oral controlled release drug delivery system using polymers: a recent review. Int J Pharm Pharm Sci 2015;7:16-21.
3. Pachuau L, Sarkar S, Mazumdar B. Formulation and evaluation of matrix microspheres for simultaneous delivery of salbutamol sulphate and theophylline. Trop J Pharm Res 2008;7:995-1002.
4. Panda S, Kumari CHS, Puniya G. Formulation and evaluation of compression coating floating tablets of carvedilol phosphate once daily dose. Int J Pharm Pharm Sci 2018;10:82-9.
5. Nallam M, Venugopalaiah P, Prakash KG, Goninath M, Naresh P. Formulation and evaluation of salbutamol sulphate extended-release tablets. Int J Curr Pharm Res 2015;3:1030-5.
6. Mallikarjun V, Babu VR, Ravi P, Narender, Rajkamala B. Formulation and evaluation of bilayered sustained release matrix tablets of salbutamol sulphate and theophylline. Inventi Rapid; Pharm Tech 2015;1:1-7.
7. Rao SK, Babu BR, Nagamounika V, Gopikapriyanka K, Sarswathi P. Formulation and optimization of sustained release matrix tablet of salbutamol sulphate. J Pharmacokinet Pharmacodyn 2015;1:1-8.
8. Parashar T, Soniya, Singh V, Singh G, Tyagi S, Patel C, et al. Novel oral sustained release technology: a concise review. Int J Res Dev Pharm Life Sci 2013;2:262-9.
9. Ummadi S, Shravani B, Rao NGR, Reddy MS, Nayak BS. Overview of controlled release dosage form. Int J Pharm Sci 2013;3:258-69.
10. Sharma PP, Sharma S, Khokra SL, Sahu RK, Jangde R, Singh J, et al. Formulation, development and evaluation of sustained release matrix tablets containing salbutamol sulphate. Pharmacologyonline 2011;1197-203.
11. Rajalaxmi G, Balachandar R, Damodharan N. Formulation and evaluation of theophylline sustained release matrix tablet. Der Pharm Lett 2011;3:1-7.
12. Kamalakkannan V, Venkartraman P, Sivaorakash R, Kumar RS, Kumaran KSGA. Formulation and evaluation of controlled release matrix tablet of salbutamol sulphate using various cellulose polymers. J Chem Pharm Res 2015;7:42-54.
13. Mote PB, Rawat PK, Singh SK, Zadbuke NS, Salunke AA, Rajendra VB, et al. Formulation and evaluation of sustained release matrix tablets of an anti-asthmatic agent using various polymers. J Drug Delivery Ther 2013;3:88-92.
14. Sujana K, Venu S, Sravani K, Iswarya P. Simultaneous estimation of salbutamol and Theophylline in bulk drugs and marketed formulation using simultaneous equation method. Int J Pharm Tech Res 2016;9:274-82.
15. Murthy PNVN, Shafiullah D, Murthy D. Formulation, development and evaluation of sustained release matrix tablets of guaiphenesin and salbutamol sulphate. Pharm Lett 2011;3:325-34.
16. Sekharan TR, Palanichamy S, Shanmuganathan S, Karthikeyan A, Senthilkumar SR, Thirupathi AT, et al. Formulation and evaluation of theophylline controlled release matrix tablets using xanthan gum. Pharm Lett 2009;1:93-101.
17. Madhavi C, Ramesh Y, Deepathi A, Gnana PK, Gobinath M, Rao SK, et al. Formulation and evaluation of sustained release matrix tablets of cefadroxil by using direct compression method. Am J Pharm Tech Res 2015;5:294-306.
18. Ramya SA, Latha K. Formulation and evaluation of zolpidem tartrate layered tablets by melt granulation technique for treatment of insomnia. Asian J Pharm Clin Res 2018;11:139-47.
19. Ain S, Kumar B, Pathak K. Development and characterization of controlled release famotidine matrix tablets containing complexes. Int J Appl Pharm 2017;9:38-46.
20. Srinivasa RB, Vjayaratana J. Formulation and evaluation of floating matrix tablets of levofloxacin and hemihydrates using hydroxymethyl propyl cellulose K4M to treat Helicobacter pylori infection. Asian J Pharm Clin Res 2018;11:148-51.